PARATEK PHARMACEUTICALS, INC. PRTK Cash Flow

Paratek pharmaceuticals, inc. (PRTK)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Net loss
-27,617	-	-	-	-35,610	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-32,083	-29,732	-27,750	-21,893	-21,324	-18,182	-27,670	-26,454	-23,628	-30,283	-31,271	-21,106	-23,422	-15,699	-10,633	-11,121	-3,233	-2,270	-1,211	17,258	-4,703	-6,708	-10,500	-6,554	4,855	-5,140	-5,177	5,296	-4,991	-2,246	-1,939
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accretion
70	-168	-231	-408	-485	-536	-820	103	187	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	354	301	1,362	358	339	244	170	150	122	272	196	-10	4	6	16	10	31	41	47	53	63	66	67	74	102	114
Stock-based compensation expense
2,535	3,553	3,824	3,055	3,863	12,537	4,085	4,503	4,367	3,884	4,082	4,892	4,044	2,690	2,659	3,024	2,419	2,122	1,513	1,186	241	199	189	303	15	-2,090	791	738	810	730	740	686	773	2,368	679	615	743
Noncash interest expense
4,542	-1,617	3,448	-1,099	2,748	-1,816	2,724	1,445	439	52	61	0	293	-531	209	206	357	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-372	288	191	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-268	-149	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	99	0	0	2,761	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in fair value of contingent consideration
-	-	-	-	-	-14	-11	-31	-15	-13	-22	-318	-231	-295	-170	15	105	-580	-240	400	-3,140	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss (gain) on mark-to-market on convertible notes and preferred stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-115	-	-	-	-	-	-	-	-	-	-	-	-
Other gains, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40	-51	1	13	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of lease liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5	-14	-108	-64	-62	-57	-91	-106
Gain on disposals of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	18	-1	0	0	0	0	-	-	-	-
Amortization of premium on available for sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-275	-225	-141	-95	-112	-145	-209	-206	-263	-362	-419
Changes in operating assets and liabilities
Accounts receivable and other current assets
2,079	-	2,648	1,056	2,348	-	425	-406	-4,985	-	-463	-226	-420	-	2,481	-2,631	-4,471	-	1,655	3,752	-3,941	-	-267	64	197	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of prepaid interest - marketable securities
-21	-	-	-	-	167	0	471	77	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventories
137	3,301	4,587	1,589	1,379	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right-of-use asset
-192	-187	-183	-178	-173	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-7,758	-1,469	4,362	-743	-1,776	-5,805	5,795	821	-1,452	871	715	-3,370	-2,439	588	-6,053	2,097	5,430	4,497	1,874	4,107	3,543	-4,077	3,783	-3,640	-2,467	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liability
-256	-250	-242	-236	-990	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities and other assets
-161	-468	-187	-505	-48	-133	-247	-195	-264	-18	-279	-164	-355	2,037	318	46	74	210	0	276	293	-	3,540	-3,207	9	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-47	-	-	-	-	-	-	-	-	-417	-625	-3,125	-3,125
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-24,927	-24,231	-29,052	-22,305	-18,510	-15,692	-21,770	-13,912	-3,308	-10,399	-2,370	-2,105	-3,659	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-119	-252	-5,787	7,138	-489	908	-1,346	2,239	-133	-292	209
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,519	-577	-48	-99	88	44	-19	340	-544	432	161
Accrued liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	190	-185	-502	-602	178	547	-681	1,101	-243	123	-350
Net cash used in operating activities
-30,326	-35,530	-28,165	-34,594	-35,756	-18,985	-20,467	-22,675	-19,052	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,807	-3,280	-4,270	-13,526	6,501	-4,633	-3,547	7,431	-5,310	-3,536	-4,292
Investing activities
Purchase of fixed assets
253	194	34	0	11	6	0	30	24	-48	37	231	897	376	-60	275	99	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	255	295	136	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10	0	2	9	22	10	2	17	2	29	11
Proceeds from Sale of Property and Equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	23	0	-	-	-	-	-	-	-	-
Purchase of marketable securities
19,631	-	-	-	-	72,132	0	171,040	49,692	30,933	55,469	66,222	27,665	42,549	25,041	-144	68,353	-	-	-	-	-	-	-	-	-	10,068	24,313	29,432	28,616	0	1	12,420	13,899	3,557	16,886	17,833
Proceeds from maturities of marketable securities
63,000	33,000	57,500	76,500	70,000	48,992	43,758	41,300	31,000	37,500	48,750	20,000	25,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
43,116	7,676	2,699	54,190	69,989	-23,146	43,758	-129,770	-18,716	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,619	-8,590	-5,604	-17,375	14,478	13,489	-5,422	-1,916	4,441	4,585	-5,844
Financing activities
Proceeds from maturities of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,450	15,700	23,830	11,250	14,500	13,500	7,000	12,000	8,000	21,500	12,000
Increase (decrease) in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	92	158	947	-	-343	214	-82	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-3,562	-4,962	-5,107	4,711	-69,399	-128	88	-509	-54	13,661	-8	1	13	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of non-convertible note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,768	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-1	111	0	176	82,474	301	-2	22	0	0	0	11	2	11	218	16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock, net of costs
9,092	-	-	-	-	1	0	0	51,516	-	3,412	41,831	36,859	9,643	-330	60,878	739	-	-	-	-	-	-	-	-	-	221	9	214	232	64	37,819	629	1,088	27	242	23
Net cash provided by financing activities
9,092	-	-	-	-	0	9,744	159,291	51,692	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	221	9	214	232	64	37,819	629	1,088	27	242	23
Net increase in cash, cash equivalents and restricted cash
21,882	-	-	-	34,233	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Refund of financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,662	0	-831	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	36,881	29,217	-330	60,878	750	694	19,368	70,653	16	91,060	3,801	712	3,937	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	33,035	6,846	13,924	2,421	-18,546	-10,468	8,392	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	24	-34,489	43,284	-87,159	-15,126	-2,314	56,232	-3,346	-	-	-	-	25,922	-4,205	-11,861	-9,660	-30,669	21,043	46,675	-8,340	6,603	-842	1,291	-10,113
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,392	291	-	-	-	-	-	-	-	-	-	-	-	-
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest
2,463	6,381	2,547	5,561	1,471	5,559	1,371	1,303	1,077	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	737	-	-	434	430	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of equipment included in accrued expenses
87	-	-	-	-	-	-	-	-	-	-	-	198	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-